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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. In the absence of high-level evidence base for follow-up practices, the duration and
frequency are often at the discretion of local centres. By reviewing the existing literature and collating
experience from varying practices across the UK, this paper provides recommendations on the work up and
management of lateral skull base cancer based on the existing evidence base for this rare condition.
Recommendations
• Patients should be followed up to a minimum of five years with a prolonged follow-up for selected patients. (G)
• Patients should be followed up at least two monthly in the first two years and three to six monthly in the
subsequent years. (G)
• Patients should be seen in dedicated multidisciplinary head and neck oncology clinics. (G)
• Patients should be followed up by dedicated multidisciplinary clinical teams. (G)
• The multidisciplinary follow-up team should include clinical nurse specialists, speech and language therapists,
dietitians and other allied health professionals in the role of key workers. (G)
• Clinical assessment should include adequate clinical examination including fibre-optic rigid or flexible
nasopharyngolaryngoscopy. (R)
• Magnetic resonance imaging and positron emission tomography combined with computed tomography
imaging should be used when recurrence is suspected. (R)
• Narrow band imaging can be used in the follow-up in selected sites. (R)
• Second primary tumours should be part of rationale of follow-up and therefore adequate screening strategies
should be used to detect them. (G)
• Patients should be educated with regard to the appearance and detection of recurrences. (G)
• Patients with persistent pain should be investigated to exclude recurrent disease. (R)
• Patients should be offered support with tobacco and alcohol cessation services. (R)
Introduction
It is accepted that the follow-up of patients who had
treatment for head and neck cancers is a fundamental
part of their care.1–4 The reasons of post-treatment
follow-up include:
• Evaluation of treatment response
• Early identification of recurrence
• Early detection of new primary tumours
• Monitoring and management of complications
• Optimisation of rehabilitation
• Provision of support to patients and their families.
Controversy exists in how these aims are achieved.5,6
Increasing efforts are beingmade to rationalise the struc-
ture and timing of head and neck follow-up clinics.
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The general structure of follow-up clinics is to have
initial high-frequency visits especially in the first two
years when the risk of loco-regional recurrence is
known to be high and then reduce frequency, with
follow-up often finishing at five years. In the UK, the
structure of these clinics is often arbitrary and reflects
institutional and clinician-led practices with very little
evidence to support any one system.
Evidence to support follow-up for early detection of
tumour recurrence is lacking. However, there is a belief
that follow-up clinics have inherent value and to date
all published studies recognise this fact.7
In order to rationalise follow-up, patients could be
divided into low and high risk. This is well recog-
nised in thyroid cancer, but it is not the case in all
other types of head and neck cancer especially squa-
mous cell carcinoma (SCC). It is a belief that, this
categorisation could help to determine which patients
should be followed for more than five years. It would
also help to establish which screening test may be




The length of follow-up is generally five years although
there are many clinicians who follow-up patients for
longer periods or even for life.8 Follow-up of patients
over five years would be justified for the following
groups: high-risk patients, specific tumours (e.g.
adenoid cystic carcinomas), patients who have under-
gone complex treatments who require on-going
rehabilitation and support, detection of new primary
tumours and patient preference. Fear of recurrence is
prevalent in cancer patients and continued attendance
at clinic helps to mitigate this.
Recommendation
• Patients should be followed up to a minimum
of five years with a prolonged follow-up for
selected patients (G)
Frequency
At present, there is no evidence that high frequency of
follow-up visits confers any benefit in terms of morbid-
ity and mortality. However, there is evidence that the
majority of clinicians in the UK support the follow-
up of patients, in regular high-frequency intervals in
the first two years when the risk of locoregional recur-
rence is high followed by a decrease in frequency after
the second year. The follow-up in the first two years
should be between four to eight weeks and from
three to six months thereafter.7
Recommendation
• Patients should be followed up at least
two monthly in the first two years and
three to six monthly in the subsequent
years (G)
Setting
At present, 90 per cent of the clinicians treating
head and neck cancer in the UK see the patients in dedi-
cated head and neck clinics for the duration of the
follow-up.
Recommendation
• Patients should be seen in dedicated
multidisciplinary head and neck oncology
clinics (G)
Type of health professional
At present patients are followed up by their treating
clinicians and their teams. Allied health professionals
including speech and language therapists, dieticians
and clinical nurse specialists may offer specific
follow-up in their areas of expertise, but this is
usually in addition to the medical follow-up. The intro-
duction of the clinical nurse specialist and the key
worker role in the management of patients with head
and neck cancer has opened lines of communication
between the patient and family and the clinical team9
should any problems arise.
Recommendations
• Patients should be followed up by the
dedicated multidisciplinary clinical teams (G)
• The multidisciplinary follow-up team should
include clinical nurse specialists, speech and
language therapists, dietitians and other allied
health professionals in the role of key
workers (G)
Clinical assessment
Traditionally, clinical assessment has been the most
important aspect of the follow-up in patients treated
for head and neck cancer. The clinical evaluation is
done by inspection, palpation and at present with
fibre-optic rigid or flexible nasopharyngolaryngoscopy.
Rigid stroboscopy can also be used in patients who have
been treated for laryngeal cancer.
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Recommendation
• Clinical assessment should include adequate
clinical examination, including fibre-optic rigid
or flexible nasopharyngolaryngoscopy (R)
Screening investigations
Currently there is evidence that magnetic resonance
imaging (MRI) and positron emission tomography
combined with computed tomography (PET–CT)
scanning are superior at detecting recurrence and
second primaries.10,11 This is especially true in some
tumour sites such as the nasopharynx and following
treatment with chemo-radiation. Positron emission
tomography combined with computed tomography
has also the advantage of being a systemic evaluation.
Diffusion-weighted MR has been recently applied with
promising results; however, its accurate interpretation
requires specific training and experience. Narrow
band imaging12 (NBI), possibly associated with high
definition television technology, has been shown to
be an adjunctive imaging tool due to its specific cap-
ability to selectively address superficial persistences
and/or recurrences or second primary tumours by
enhancing their pathognomonic neoangiogenetic
pattern. It has been reported that its use can detect 18
per cent more true positive laryngeal cancerous
lesions than conventional white light endoscopy. This
is true even after radiotherapy (RT) or chemoradiother-
apy, due to the high accuracy (98 per cent) of NBI in
differentiating between neoplastic disease and post-
RT inflammatory and/or cicatricial changes.
Recommendations
• Magnetic resonance imaging and PET–CT
imaging should be used when recurrence is
suspected (R)
• Narrow band imaging can be used in the
follow-up in selected sites (R)
Second primary tumours
The incidence of second primary tumours varies
between 5 and 12 per cent at five years. There is
good evidence to indicate that patients with head
and neck SCC have an increased risk of developing
second primary malignant tumours.13,14 This risk
appears to be constant throughout the follow-up
period, with an incidence ranging from 2 to 4 per
cent per year. Traditionally, patients undergoing
follow-up for head and neck cancer underwent a
chest radiograph every year. However, there is
evidence that these have not been able to identify
metastasis with any confidence.
Recommendation
• Second primary tumours should be part of
rationale of follow-up and therefore adequate




In laryngeal cancer, especially in those patients treated
with transoral laser microsurgical excision, it is advis-
able to perform second-look microlaryngoscopy,15
especially in scenarios where there is lack of agreement
between the intraoperative and histological findings
regarding the completeness of resection. The rationale
of this is to provide evidence of complete resection,
detect residual tumour and to perform further treatment
should this be necessary.
Patients with persistent or recurrent pain without
clinical evidence of disease
Pain complaints must be regarded as a serious warning
sign of recurrent disease during follow-up of HNC
patients,16,17 even in the absence of an endoscopically
visible persistence and/or recurrence. Persistent neck
pain can be the first symptom of recurrent disease in
70 per cent of patients and can be an independent pre-
dictor of both recurrence and five-year survival rate.
Pain should always prompt the clinician to initiate a
thorough set of investigations, both by imaging and/
or endoscopy under general anaesthesia, in order to
reduce possible diagnostic delays. Pain without endo-
scopic evidence of disease is more frequently encoun-
tered after RT or chemoradiotherapy, but it is possible
even after surgery. This symptom is usually caused by
submucosal disease recurrence possibly hidden by
oedematous mucosa, or associated with chondritis,
chondronecrosis or osteonecrosis as a result of previ-
ous treatments.
Tumour markers
There is no evidence that the use of tumour markers is
any value in the follow-up of patients with head and
neck SCCs. The use of tumour markers in the follow-
up of patients with thyroid cancer is addressed else-
where in these guidelines.
Patient education
It has been recognised that the education of patients
plays an essential role in the detection of recurrences.
The vast majority of recurrences are diagnosed follow-
ing the occurrence of new symptoms and thus patients
should be educated about the need to seek help when
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appropriate. It has also been recognised that continuing
smoking and alcohol drinking increases the risk of
recurrence and second primary tumours. It is therefore
imperative that patients are advised and offered support
with regards to the detrimental effects of tobacco
smoking and alcohol addiction.
Recommendations
• Patients should be educated with regards to the
appearance and detection of recurrences (G)
• Patients with persistent pain should
investigate to exclude recurrent disease (R)
• Patients should be offered support with
tobacco and alcohol cessation services (R)
Key points
• The aims of follow up of patients after treatment
for head and neck cancers are manifold
• The frequency of follow-up is higher in the first
two years, with reduced frequency subsequently,
finishing at five years
• Medical, nursing and allied health professionals
all play important roles in providing follow up care
• Change in patient symptoms during follow up is
the most frequent indication of recurrent disease
and must be regarded seriously, even if clinical
examination reveals no abnormalities.
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